People | January 20, 2022
AstraZeneca India appoints Ram Mudaliar as India lead of their CDI division
Ram’s appointment follows the launch of the CDI India division in October 2021.
Ram’s appointment follows the launch of the CDI India division in October 2021.
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha, Gamma and Omicron variants following third dose booster with Vaxzevria
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
The company will manufacture a cancer immunotherapy product from 2022
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
The Board of Directors of AstraZeneca Pharma India have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
Subscribe To Our Newsletter & Stay Updated
